1. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K212871.
2. Single-needle delivery of pulsed electric fields (PEF) energy to early-stage non- small cell lung cancer (NSCLC): feasibility and safety near sensitive structures in the INCITE ES study;Jimenez;J. Vasc. Intervent. Radiol.,2023
3. Single-needle delivery of pulsed electric fields (PEF) energy to early-stage non- small cell lung cancer (NSCLC): feasibility and safety near sensitive structures in the INCITE ES study;Jimenez;J. Vasc. Intervent. Radiol.,2023
4. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer;Antonia;N. Engl. J. Med.,2017
5. Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in stage III non-small-;Spigel;Cell Lung Cancer J Clin Oncol,2022